EGFR and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain are typically treated with the EGFR tyrosine kinase inhibitor, erlotinib.